The Application of Knowledge-Based Clinical Decision Support Systems to Detect Antibiotic Allergy

Prevention of drug allergies is important for patient safety. The objective of this study was to evaluate the outcomes of antibiotic allergy-checking clinical decision support system (CDSS), K-CDS<sup<TM</sup<. A retrospective chart review study was performed in 29 hospitals and antibiotic allergy alerts data were collected from May to August 2022. A total of 15,535 allergy alert cases from 1586 patients were reviewed. The most frequently prescribed antibiotics were cephalosporins (48.5%), and there were more alerts of potential cross-reactivity between beta-lactam antibiotics than between antibiotics with the same ingredients or of the same class. Regarding allergy symptoms, dermatological disorders were the most common (38.8%), followed by gastrointestinal disorders (28.4%). The 714 cases (4.5%) of immune system disorders included 222 cases of anaphylaxis and 61 cases of severe cutaneous adverse reactions. Alerts for severe symptoms were reported in 6.4% of all cases. This study confirmed that K-CDS can effectively detect antibiotic allergies and prevent the prescription of potentially allergy-causing antibiotics among patients with a history of antibiotic allergies. If K-CDS is expanded to medical institutions nationwide in the future, it can prevent an increase in allergy recurrence related to drug prescriptions through cloud-based allergy detection CDSSs..

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:13

Enthalten in:

Antibiotics - 13(2024), 3, p 244

Sprache:

Englisch

Beteiligte Personen:

Nayoung Han [VerfasserIn]
Ock Hee Oh [VerfasserIn]
John Oh [VerfasserIn]
Yoomi Kim [VerfasserIn]
Younghee Lee [VerfasserIn]
Won Chul Cha [VerfasserIn]
Yun Mi Yu [VerfasserIn]

Links:

doi.org [kostenfrei]
doaj.org [kostenfrei]
www.mdpi.com [kostenfrei]
Journal toc [kostenfrei]

Themen:

Antibiotics
Clinical decision support systems
Drug allergy
Knowledge database
Therapeutics. Pharmacology

doi:

10.3390/antibiotics13030244

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

DOAJ100882900